Email this article 
Néoplasies myéloprolifératives (NMP) – Partie 2 : Guide infirmier sur la conduite à tenir devant les symptômes de NMP
Abstract
Les néoplasies myéloprolifératives (NMP) sont des troubles rares mais potentiellement mortels causés par la production excessive de cellules souches dans la moelle osseuse. Chez les patients atteints de NMP sans mutation du gène BCR-ABL1 (c.-à -d. la thrombocytémie essentielle [TE], la polycythémie vraie [PV] et la myélofibrose [MF], aussi appelées « NMP classiques »), les symptômes peuvent être incapacitants et nuire à la qualité de vie. Malgré tout, il est possible pour les patients souffrant de ces types de NMP de vivre plusieurs années, moyennant un traitement et un suivi à long terme. Les infirmières jouent alors un rôle essentiel pour favoriser la communication avec ces patients, évaluer les symptômes et leur enseigner les traitements et les stratégies d’autosoins pouvant les apaiser. Le présent article, second d’une série de deux, présentera aux infirmières et autres professionnels de la santé des conseils pratiques pour traiter la symptomatologie associée aux NMP et ainsi améliorer la santé générale et la qualité de vie des patients.
Full Text:
PDFReferences
BC Cancer Agency. (2005). Nutritional Guidelines for Symptom Management: Early Satiety. Available online at http://www.bccancer.bc.ca/nutrition-site/Documents/Symptom%20management%20guidelines/EarlySatiety.pdf
Centers for Disease Control and Prevention. (2013). Chronic Fatigue Syndrome. Available at: https://www.cdc.gov/cfs/management/treating-symptoms.html
Cervantes, F. (2011). How I treat splenomegaly in myelofibrosis. Blood Cancer Journal, 1(10), e37.
Emanuel, R.M., Dueck, A.C., Geyer, H.L., Kiladjian, J.J., Slot, S., Zweegman, S., te Boekhorst, P.A., … Mesa. R.A. (2012). Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology, 30(33), 4098–4103.
Geyer, H.L., Dueck, A.C., Scherber, R.M., & Mesa, R.A. (2015). Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators of Inflammation, 2015, 284706.
Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., … Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787–98.
Harrison, C.N., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Knoops, L., Cervantes, F., … Barbui, T. (2016). Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib versus best available therapy for myelofibrosis. Leukemia, 30, 1701–1707.
Hermouet, S., Bigot-Corbel, E., & Gardie B. (2015). Pathogenesis of myeloproliferative neoplasms: Role and mechanisms of chronic inflammation. Mediators of Inflammation, 2015, 145293.
Howell, D., Keshavarz, H., Broadfield, L., Hack, T., Hamel, M., Harth, T., Jones, J., … Ali, M, on behalf of the Cancer Journey Advisory Group of the Canadian Partnership Against Cancer. (2015). A Pan Canadian Practice Guideline for Screening, Assessment, and Management of Cancer-Related Fatigue in Adults Version 2-2015, Toronto: Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and the Canadian Association of Psychosocial Oncology, April 2015.
Mesa, R.A., Gotlib, J., Gupta, V., Catalano, J.V., Deininger, M.W., Shields, A.L., Miller, C.B., … Verstovsek, S. (2013). Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 31(10), 1285–1292.
Mesa, R., Miller, C.B., Thyne, M., Mangan, J., Goldberger, S., Fazal, S., Ma, X., … Mascarenhas, J.O. (2016). Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer, 16, 167.
Mesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., … Tefferi, A. (2007). The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPN patients. Cancer, 109(1), 68–76.
Mesa, R.A., Scherber, R.M., & Geyer, H.L. (2015). Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leukemia & Lymphoma, 56(7), 1989–1999.
Michiels J.J. (2016). Signs and symptoms of myeloproliferative neoplasms (MPN), quality of life, social activity, work participation and the impact of fatigue in Dutch MPN patients: A one-country questionnaire investigation of 497 MPN patients. Journal of Hematology and Thromboembolic Diseases, 4, 241.
Mughal, T.I., Vaddi, K., Sarlis, N.J & Verstovsek, S. (2014). Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine, 7, 89–101.
Neben-Wittich, M.A., Brown, P.D., & Tefferi, A. (2010). Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fractionradiation therapy. American Journal of Hematology, 85(10), 808–810.
Radia, D., & Geyer, H.L. (2015). Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematology Am Soc Hematol Educ Program, 2015, 340–348.
Saini, K.S., Patnaik, M.M., & Tefferi, A. (2010). Polycythemia vera-associated pruritus and its management. European Journal of Clinical Investigation, 40(9), 828–834.
Scherber, R., Dueck, A.C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., … Mesa, R.A. (2011). The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood, 118(2), 401–408.
Scherber, R.M., Kosiorek, H.E., Senyak, Z., Dueck, A.C., Clark, M.M., Boxer, M.A., Geyer, H.L., … Mesa, R.A. (2016). Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer, 122, 477–85.
Vannucchi, A.M., Kiladjian, J,J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., … Verstovsek, S. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(5), 426–435.
Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., … Kantarjian, H.M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366(9), 799–807.
Refbacks
- There are currently no refbacks.
